Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety Authors: Shu-jie Li, Qing-ning Yuan, Wen-yuan Wu, Zhi-han Chen, Duo Chen, Hong Shan, Qin-yu Chu, Wen Hu, Kai Wu, Tao Liu, Yu-yu Zhu, Li Hou, Jing Zhou, Jia Duan, Jin-ao Duan, H. Eric Xu, Hong-yue Ma Published: 2025 ABSTRACT The 5-HT1A receptor is a critical target in the treatment of depression and anxiety. Bufotenine derivatives, such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-hydroxy-N,N-dimethyltryptamine (5-OH-DMT), and 5-hydroxy-N,N,N-dimethyltryptamine—derived from traditional Chinese medicine—have shown antidepressant potential. However, the structural basis of their interaction with 5-HT1A and their pharmacological profiles remain incompletely understood. This study investigated bufotenine derivatives acting on multiple serotonin receptors, highlighting 5-HT1A as a key mediator of antidepressant effects while recognizing 5-HT2A as primarily responsible for hallucinogenic outcomes, to identify candidates with therapeutic efficacy but reduced hallucinogenic liability. We determined the cryo-electron microscopy structures of 5-HT1A bound to selected bufotenine derivatives. Functional assays in mice, including behavioral tests and receptor activation studies, were used to evaluate the antidepressant of each compound. Structural analysis revealed that all bufotenine derivatives engage conserved motifs within the 5-HT1A binding pocket, with 5-OH-DMT displaying a distinct interaction pattern. Behavioral assays showed that 5-OH-DMT and 5-MeO-DMT retained strong antidepressant and anxiolytic effects. These pharmacological differences correlate with their unique receptor binding conformation. This study delineated the structural pharmacology of bufotenine derivatives at the 5-HT1A receptor, identifying 5-OH-DMT and 5-MeO-DMT as promising antidepressant and anxiolytic candidates. The findings establish a molecular framework for the development of next-generation nonhallucinogenic therapeutics aimed at 5-HT1A. Introduction Depression is a prevalent mental illness that affects the quality of life and psychosocial performance. It causes depression, anhedonia, poor self-esteem, guilt, worthlessness, weariness, sleep problems, and suicidal thoughts [1,2]. Standard antidepressants like monoamine oxidase inhibitors and selective serotonin reuptake inhibitors regulate central nervous system monoamine neurotransmitter levels. The therapeutic effects of these drugs usually take weeks to appear [3]. About two-thirds of patients relapse or do not respond to these treatments [4,5]. The monoamine hypothesis, which states that neurotransmitter imbalances in serotonin (5-HT), norepinephrine, and dopamine cause depression, underpins the efficacy and pharmacodynamics of first- and second-generation antidepressants [6,7]. Depressive disorders may be caused by at least 6 serotonin receptor subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, and 5-HT7), according to emerging evidence [8,9]. Serotonin dysregulation is largely considered a key cause of severe depressive illness. The neuropathology of depression depends on the 5-HT1A receptor (5-HT1AR), the main serotonin receptor [10,11]. 5-HT1AR regulates melancholy and anxiety [12]. In mice, 5-HT1AR-deficient animals exhibit increased anxiety, dread, and freezing, demonstrating its function in anxiety regulation [13]. In addition, overexpression of 5-HT1AR in the forebrain during early postnatal development, but not in the raphe nuclei, restores conventional behavioral features in knockout mice, underscoring the importance of postsynaptic 5-HT1AR in mental health [14]. Mice and primates with reduced 5-HT1AR expression exhibit anxiety and stress-related behaviors [15,16]. Both psychedelics and selective 5-HT1AR agonists exhibit anxiolytic properties through distinct yet partly overlapping mechanisms. Clinically used 5-HT1A agonists such as buspirone alleviate anxiety by modulating serotonergic signaling and stress-coping pathways. Psychedelics like psilocybin, which also engage 5-HT1ARs alongside 5-HT2A activation, demonstrate additional anxiolytic and antidepressant potential. 5-HT1AR is a target of licensed anxiolytic and antidepressant drugs including buspirone (BuSpar) [17] and vilazodone (Viibryd) [18]; therefore, knowing its processes is crucial to improving depression therapies. Through Gi/o family heterotrimeric G proteins, 5-HT1AR inhibits adenylyl cyclase and lowers cyclic adenosine monophosphate (cAMP) levels, and this effect is enhanced by 5-HT1AR agonists [19]. Despite extensive investigation, the molecular abnormalities in the serotonin pathway linked to clinical depression and suicidality are still unknown. Traditional antidepressants have limited effectiveness, extensive treatment times, and lasting adverse effects, underscoring the need for innovative and fast-acting treatments [20–22]. Psychoactive bufotenine compounds from Bufo alvarius toad parotid glands affect humans and animals. Bufotenine, a natural tryptamine in Ch’an Su, has been utilized in Chinese medicine for centuries [23]. Bufotenine derivatives have an indole core, an amino group, and an ethyl side chain like serotonin. These derivatives include 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-hydroxy-N,N-dimethyltryptamine (5-OH-DMT), and 5-hydroxy-N,N,N-dimethyltryptamine (5-OH-TMT). Studies reveal that indole ring alterations at position 5 increase potency relative to that of other substituted and unsubstituted tryptamines [24], but clinical effects are similar [25]. Recent discoveries that hallucinogens may treat depression, anxiety, drug use disorders, and obsessive-compulsive behaviors have increased interest in their pharmacology [26,27]. Some tryptamines, both 5-MeO-substituted and unsubstituted, block or release 5-HT [28]. This combined mechanism of 5-HT reuptake inhibition and receptor interaction may be better than selective serotonin reuptake inhibitors for mood disorders [29]. Most structure–activity relationship research on tryptamines has concentrated on indole ring replacements, with few investigations on terminal amino group modifications [30]. Some 5-MeO-tryptamines bind with the 5-HT2A receptor (5-HT2AR), although they usually work better at 5-HT1AR [31,32]. However, inconsistent results have been reported [28]. Additionally, bufotenine derivatives’ 5-HT1AR modulation effect in depression therapy is unknown. Extensive research has established that psychedelics function as 5-HT2AR agonists, capable of inducing profound alterations in perception, cognition, and mood states [33]. However, emerging evidence suggests that the therapeutic efficacy of 5-HT2AR agonists may not necessarily depend on psychedelic experiences, with studies demonstrating that psilocybin’s antidepressant effects can occur independently of both 5-HT2AR activation and associated psychedelic activity [9,34,35]. These findings highlight a critical knowledge gap regarding the mechanistic relationship between psychedelic properties and therapeutic outcomes in 5-HT2AR-targeted interventions. The clinical translation of psychedelic-based therapies faces substantial methodological and practical challenges. The compounds’ intrinsic psychoactive properties fundamentally undermine the integrity of double-blind clinical trial designs, while the standard practice of combining pharmacological intervention with psychotherapy obscures the precise attribution of therapeutic benefits. Additional concerns regarding long-term safety profiles and potential for nonmedical use further complicate their clinical implementation. Motivated by increasing scientific interest in microdosing protocols for cognitive enhancement and mood regulation [36], we sought to develop a novel therapeutic agent that maintains robust antidepressant efficacy while exhibiting minimized psychedelic properties, thereby addressing current limitations in the field. This study explored the structural and functional mechanisms of how bufotenine derivatives, namely, 5-MeO-DMT, 5-OH-DMT, and 5-OH-TMT, bind to and activate 5-HT1AR at molecular and atomic levels. Furthermore, we systematically investigated the therapeutic potential of bufotenine derivatives in established mouse models of depression. Our study shows that 5-OH-DMT acts on multiple serotonin receptors, with 5-HT1A contributing to its antidepressant and anxiolytic effects and reduced 5-HT2A involvement accounting for diminished hallucinogenic activity. These results provide a pharmacological foundation for the development of next-generation antidepressant therapies with targeted 5-HT1AR engagement. Results Bufotenine derivatives acting at 6 depression-related serotonin receptors We evaluated the impact of bufotenine derivatives on 6 serotonin receptor subtypes associated with depression (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, and 5-HT7) using the GloSensor cAMP assay to measure Gi and Gs activation and the IP-One assay to assess Gq activation, thereby detecting signaling activity at each receptor. All synthesized bufotenine derivatives demonstrated potency at 5-HT receptor subtypes, with particularly pronounced potency and efficacy observed at 5-HT1ARs (Fig. 1A). 5-OH-DMT demonstrated the greatest potency for 5-HT1AR with an EC50 of 0.1 μM. The activation potency at 5-HT1AR was lower for 5-MeO-DMT (EC50 = 0.5 μM) and 5-OH-TMT (EC50 = 10 μM) compared to those for other tryptamines. We conducted a thorough pharmacological analysis of bufotenine derivatives to evaluate their hallucinogenic potential via 5-HT2AR activation, comparing their receptor binding profiles and functional activities at 5-HT1AR and 5-HT2AR subtypes. 5-MeO-DMT demonstrates markedly greater potency at 5-HT2AR (EC50 = 0.01 μM) compared to 5-OH-DMT (EC50 = 1 μM), being 100 times more potent. 5-OH-TMT showed a similar attraction to 5-HT1ARs (EC50 = 10 μM). The efficacy of 5-HT1AR was greater for these compounds compared to that of 5-HT2AR. Bufotenine derivatives generally showed greater potency for 5-HT1AR than for 5-HT2AR. The functional profile of 5-MeO-DMT closely aligns with the recently reported structural findings [37], with an approximately 10-fold difference in EC50 values, a variation that remains within an acceptable and interpretable range. In our experiments, bufotenine derivatives acted as full agonists in 5-HT1A-mediated G-protein signaling compared to serotonin, despite variations in selectivity and potency. These findings validate the potency and efficacy of 5-MeO-DMT at 5-HT1A, corroborating previous research highlighting the importance of 5-HT1A in vivo pharmacology [38,39]. Our research demonstrates that 5-OH-DMT exhibits greater efficacy as a 5-HT1A agonist compared to 5-MeO-DMT and 5-OH-TMT, with 5-OH-TMT being the least potent. Bufotenine derivatives acting at 6 depression-related serotonin receptors. (A) The difference of bufotenine derivative in activating depression-related serotonin receptors. (B) Schematic illustration of G-protein coupling of 5-HT1A activated by a bufotenine derivative. 5-HT, serotonin; 5-HT1AR, 5-HT1A receptor; 5-HT1BR, 5-HT1B receptor; 5-HT1DR, 5-HT1D receptor; 5-HT2AR, 5-HT2A receptor; 5-HT2CR, 5-HT2C receptor; 5-HT7R, 5-HT7 receptor; 5-MeO-DMT, 5-methoxy-N,N-dimethyltryptamine; 5-OH-DMT, 5-hydroxy-N,N-dimethyltryptamine; 5-OH-TMT, 5-hydroxy-N,N,N-dimethyltryptamine. Structures of bufotenine-derivative-bound 5-HT1A We generated 5-HT receptor–Gi complexes by coexpressing the receptors with a dominant-negative variant of human Gαi1 [40] and human Gβγ. The 5-HT1A–Gi complexes coupled to 5-OH-TMT, 5-MeO-DMT, or 5-OH-DMT were analyzed, and their structures were determined at a resolution of 2.6 to 2.9 Å. The 5-MeO-DMT-bound 5-HT1A–Gi complex and the 5-OH-DMT-bound HT1A–Gi complex structures were resolved at a 2.9-Å resolution. The cryo-electron microscopy (cryo-EM) maps offer sufficient clarity to accurately identify the positions of the receptor, G-protein trimer, and bound ligands within the receptor–G-protein complexes (Fig. 2A to C, Figs. S1 to S4, and Table S1). Our structure shows a high degree of similarity to the recently reported 5-MeO-DMT–5-HT1A complex, with only minor differences (Fig. S6F) [37]. The cryo-EM maps of 5-HT1A with 5-OH-TMT, 5-MeO-DMT, and 5-OH-DMT show unique structures that align precisely with a phosphatidylinositol-4-phosphate (PtdIns4P) molecule [41]. Our previous research demonstrated that PtdIns4P acts as a positive allosteric modulator of 5-HT1A by enhancing its basal activity and facilitating Gi recruitment and that 5-HT1A is further surrounded by diverse lipid species at the membrane interface [41]. Cryo-electron microscopy (cryo-EM) structures of 5-MeO-DMT–5-HT1A–Gi–scFv16, 5-OH-DMT–5-HT1A–Gi–scFv16, and 5-OH-TMT–5-HT1A–Gi–scFv16 complexes. (A to C) Cryo-EM density maps (A and C) and cartoon representation (B) of 5-MeO-DMT–5-HT1A–Gi–scFv16, 5-OH-DMT–5-HT1A–Gi–scFv16, and 5-OH-TMT–5-HT1A–Gi–scFv16. Composite DeepEMhancer sharpened cryo-EM density maps colored by protein components. PtdIns4P, phosphatidylinositol-4-phosphate. Binding mode of bufotenine derivatives at 5-HT1A The structures we have discovered demonstrate distinct interactions between drugs and receptors within the orthosteric binding pocket (OBP), perhaps resulting in variations in pharmacological effects. The binding position of bufotenine derivatives in 5-HT1AR complexes closely resembles that of serotonin within the receptor’s structure (Fig. 3A and B). Bufotenine derivatives binding to the orthosteric pocket of 5-HT1A complexes apply downward pressure on the toggle switch residue W3586.48 (Fig. S5A), leading to conformational changes in F3546.44 and I1243.40 within the PIF motif (Fig. S5B) and R1343.50 in the DRY motif (Fig. S5C). Conformational changes disrupt the conserved ionic lock between TM3 and TM6, leading to a notable outward shift of TM6 by approximately 13.7 Å at the Cα of E3406.30 at the cytoplasmic end of TM6 (Fig. 3C). The inward shift of approximately 5.3 Å at the cytoplasmic end of TM7 enables hydrogen bonding between the Y4007.53 of the NPxxY motif and Y2155.58 with the R1343.50 of the DRY motif (Fig. 3D and E). These conformational alterations facilitate the accessibility of the receptor’s cytoplasmic pocket for Gi binding. Structural features of 5-HT1A in the active state by bufotenine derivatives. (A and B) Structural superposition of bufotenine-derivative-bound 5-HT1A and 5-HT-bound 5-HT1A, presented from both the side view (left) and top view (right). (C to E) Conformational changes of the conserved “microswitches” upon receptor activation. The outward movement of the TM7 of the active receptor and the conformational changes of residue side chains are highlighted as black arrows. (F to H) Polar interaction network that stabilizes the conformation of bufotenine-derivative-bound 5-HT1A, respectively (dotted blue line, hydrogen bonds; ochre brown, salt bridges; dotted green line, π–π interactions). The identification of bufotenine derivatives relies on 2 key chemical elements: the indole ring and the ethylamine side chain (Fig. S6A to C), which mostly occupy the OBP. The indole ring serves as the fundamental structure of bufotenine derivatives. The indole ring primarily participates in π–π interactions with F3616.51 and F3626.52, as Ballesteros–Weinstein numbering (Fig. 3F to H) [42]. In the lower region of the 5-HT1A binding pocket, the indole nitrogen of bufotenine derivatives establishes a hydrogen bond with T1213.37 (Fig. 3F to H), causing a 16.0° to 39.3° angle rotation of the bufotenine derivatives around the axis of the indole nitrogen (Fig. S6D). Bufotenine derivatives are primarily distinguished by the position of the indole ring, specifically at the 3 and 5 locations, with an ethylamine side chain attached to the 3 position (Fig. S6A to C). This side chain imparts tryptamine characteristics to the bufotenine derivatives. The indole ring has a hydroxyl group at the 5-position. This property also differentiates the bufotenine derivatives from one another (Fig. S6A to C). Furthermore, the indole ring of 5-OH-DMT establishes a hydrophobic contact with I189ECL2 located in extracellular loop 2 of 5-HT1AR (Fig. S6E). This is a notable distinction among the 3 derivatives that is not observed in the other 2 compounds. Both 5-OH-DMT and 5-OH-TMT were observed to have the indole ring interacting with I1674.56; however, this interaction was not observed in 5-MeO-DMT (Fig. 3F to H). Additionally, the indole ring forms notable interactions with adjacent residues within the pocket, including V1173.33, S1995.42, T2005.43, A2035.46, and A3656.51 (Fig. 3F to H and Fig. S7). The ethylamine side chain has the ability to establish a hydrogen bond with the nearby D1163.32, which results in a certain alignment of the bufotenine derivatives (Fig. 3F to H). The positive charge on the ethylamine side chain of 5-OH-TMT prevents additional hydrogen bonding with adjacent nitrogen atoms. Nevertheless, this favorable charge also promotes the stability of the ligand within the pocket by salt bridge interactions (Fig. 3H). The ethylamine side chain interacts with the receptor via residues C1203.36, W3586.48, N3867.39, and Y3907.43 (Fig. S6E). In general, the alterations made to the ligand do not change the way it binds. Similar to the binding mechanism of serotonin, we discovered that the sites D1163.32 and T1213.37 were crucial in the binding of bufotenine derivatives to 5-HT1A (Fig. S6E). Following the mutation of the D1163.32 and T1213.37 sites to alanine, EC50 decreased by around 100-fold. Through the alanine mutants of F3616.51 and W3586.48, we discovered a significant decrease in the potency of the 3 bufotenine derivatives in activating 5-HT1AR (Fig. S7 and Table S2). F3616.51 stabilizes the tryptamine scaffold’s structure and is essential for the efficacy of different amine replacements. Previous studies have shown that A3616.51, located adjacent to the 4-indole and 5-indole substituents in the 5-HT receptor, is specifically linked to 5-HT1AR and is essential for determining its ligand selectivity (Fig. 2G to I and Fig. S7B, E, and H). In order to examine the underlying mechanism of ligand selectivity, we introduced a mutation at position A3656.55, replacing it with phenylalanine. We detected a reduction in the potency of all analyzed tryptamine derivatives, with 5-OH-DMT exhibiting the most significant loss in potency, estimated to be around 1,000-fold less potent (Fig. S7E). Therefore, the presence of A3656.55 in 5-HT1AR is crucial for the strong effectiveness of 5-substituted tryptamines. This may be because A3656.55 has the capacity to accept groups with diverse chemical characteristics. Structural insights from bufotenine-derivative-bound 5-HT2AR To investigate the variations in the strength of bufotenine derivatives at 5-HT1AR and 5-HT2AR, we employed molecular docking to forecast the arrangement of bufotenine derivatives binding with 5-HT2A (PDB: 7RAN). In comparison to 5-HT2AR, 5-HT1AR exhibited an outward displacement of about 8.1 Å in the TM6 region, whereas TM8 was elevated by almost 2 Å (Fig. 4A). This change may be associated with the binding of PtdIns4P between TM6 and TM7. It is important to mention that 5-MeO-DMT has greater interactions with the V2355.39 and F2345.38 residues on TM5 in 5-HT2A. This, together with the influence of L229ECL2, causes a shift of about 1.89 Å toward TM5 (Fig. 4B). The structural analysis of 5-OH-DMT–5-HT2A reveals that the I1633.40 residue on TM3 and the V2355.39 residue on TM5 interact with the ligand (Fig. 4C). Unfortunately, the I1674.56 residue site is absent on TM4. Furthermore, the indole ring of the ligand linked to 5-HT2A undergoes a 25° upward rotation when N3436.55 replaces A3656.55 on 5-HT1A TM6 (Fig. 4D). These circumstances may cause a significant drop in potency and reduced efficacy with 5-HT2A, roughly 10 times lower than normal (Fig. 1A). The occurrence of 5-OH-TMT in 5-HT2A results in a displacement of about 1.18 Å toward TM5. This displacement might be attributed to the lack of I1674.56 on TM4 and the presence of V2355.39 on TM5 (Fig. 4E). Mutation data also demonstrated that 5-OH-TMT exhibited no alteration in affinity for both receptors but displayed a small increase in activity specifically toward 5-HT1A. In the structural comparison, the indole ring of bufotenine derivatives in 5-HT1A is rotated about 26.6° relative to 5-HT2A, altering the local polarity effect (Fig. 4F). Structural comparison of bufotenine derivatives in relation to 5-HT1AR, 5-HT1BR, and 5-HT2AR. (A) 5-HT1AR displaces TM6 and TM8 outward and downward during activation, attributed to PtdIns4P binding between TM6 and TM7. Aligned structures of the inactive-state 5-HT1B (bound to the inverse agonist methiothepin; PDB: 6G79). (B) Unlike the 5-MeO-DMT–5-HT1A structure, 5-MeO-DMT–5-HT2A shifts the ligand toward TM5 during activation. (C and D) The 5-OH-DMT–5-HT1A structure experiences rotation of the indole ring during activation. (E) The ligand is shown to migrate toward TM5 in the 5-OH-TMT–5-HT2A structure. (F) In contrast to 5-HT2A, the indole ring of bufotenine derivatives in 5-HT1A is rotated, modifying the local polarity effect. The black arrows indicate the trajectory of the receptor helix or the residues’ side chain’s migration. Structures of therapeutic drugs bound to 5-HT1A 5-HT1A serves as a therapeutic target for the anxiolytic medication buspirone and the antidepressant vilazodone, both of which are often utilized in clinical practice. In the comparison of commonly used clinical drugs, we conducted functional experiments. The findings indicated that the EC50 values of 2 buprenorphine derivatives were approximately comparable to those of clinically utilized drugs (Fig. 5A). All 6 compounds reside in the OBP; however, they exhibit varying depths and an extended binding pocket (PDB: 7E2Z, 8FYL, and 8FYX) (Fig. 5B). Buspirone had the highest potency, with an EC50 of 1 nM. 5-MeO-DMT, 5-OH-DMT, aripiprazole, and vilazodone exhibited comparable affinities, with EC50 spanning around 10 to 100 nM. Unlike tryptamine derivatives, aripiprazole may interact with the N3877.40 residue site on TM7, a unique binding site believed to stabilize the quinolone segment of aripiprazole inside the 5-HT1A extended binding pocket (Fig. 5C). The vilazodone molecule contains an indole core that is connected to the OBP. The W3877.40 residue on TM7 and the Y962.64 residue on TM2 exhibit π–π interactions with the benzofuranocarboxamide group of vilapatone (Fig. 5D). Aripiprazole and exrazolone possess similar OBP structures, characterized by the inward rotation of the indole ring at W3877.40 and the phenolic hydroxyl group at Y962.64, hence augmenting polar contacts, in stark contrast to the tryptamine derivatives. The benzofurancarboxamide moiety of vilazodone extends toward the extracellular site, whereas the piperazine part is positioned closer to the extracellular area compared to other compounds. The presence of this characteristic may be attributed to the distinct binding configurations of vilazodone and aripiprazole. In particular, the N-aryl substituent of aripiprazole and the N-alkyl substituent of vilazodone attach to the OBP, causing D1163.32 and Y3907.43 to interact with the identical piperazine in both drugs (Fig. 5E). The prolonged pocket in the structure of buspirone is maintained by the involvement of M922.60, A932.61, and C187ECL2 at the TM2 location. Buspirone has a distorted structural conformation, whereby the azacyclodecane-7,9-dione component curves into the interstice between TM2 and TM3, causing the side chains of M922.60 and F1123.28 to rotate outward accordingly (Fig. 5F). Within the context of the OBP, the piperazine component of buspirone engages with D1163.32 in a way akin to aripiprazole (Fig. S5D). Specifically, the pyrimidine portion of buspirone is positioned in close proximity to TM3 and TM5, resulting in mostly hydrophobic interactions (Fig. S5E). In general, we see that although they have distinct structures, vilazodone, aripiprazole, and buspirone have comparable orientations in the central binding pocket. The aromatic piperazine substituents of these compounds are mostly stabilized by phenylalanine residues in TM6 (F3616.51 and F3626.52) (Fig. S5F). Therefore, it may be inferred that bufotenine derivatives have pharmacological actions that are comparable to those of antidepressants, as they display a similar binding pattern in the OBP. Structural and functional comparison of bufotenine derivatives and clinical 5-HT1A medications at 5-HT1A. (A) 5-HT1A–Gi GloSensor assays of 5-HT, 5-MeO-DMT, 5-OH-DMT, 5-OH-TMT, vilazodone, aripiprazole, and buspirone. All signaling experiments were performed in triplicate and were averaged from 3 independent experiments. Data were normalized against 5-HT, and errors bars denote the standard error of the mean (SEM). (B) Comparison of the positioning of bufotenine derivatives and therapeutic 5-HT1A medications inside the 5-HT1AR pocket. (C) The quinolone segment of aripiprazole influences alterations in the side chain of the N3877.40 residue and the displacement of TM7 inside the 5-HT1A extended binding pocket. (D) Vilapatone’s benzofuranocarboxamide group affects the displacement of TM7 inside the 5-HT1A extended binding pocket as well as changes to the side chain of the N3877.40 residue. (E) The N-aryl substituent of aripiprazole and the N-alkyl substituent of vilazodone attach to the orthosteric binding pocket (OBP). (F) The azacyclodecane-7,9-dione component of buspirone curves into the interstice between TM2 and TM3. The black arrows indicate the trajectory of the receptor helix or the residues side chain’s migration. EBP, extended binding pocket. 5-OH-DMT and 5-MeO-DMT exhibited similar improvement against depressive-like behaviors through 5-HT1AR We explored the therapeutic effects of 5-MeO-DMT and 5-OH-DMT on depression and the involvement of 5-HT1AR by stereotactically injecting AAV with Syn-eGFP-sh-5-HT1AR to knock down 5-HT1AR in the hippocampus (Figs. S8 and S9). Here, we focused on 5-HT1AR in the mouse hippocampus, because the hippocampus is of particular importance in regulating mood and adult neurogenesis, as well as the highest levels of 5-HT1AR in the hippocampal area [43–45]. Mice were subjected to chronic unpredictable mild stress (CUMS) to model depression, and their condition was assessed through behavioral tests (Fig. S8A). CUMS prolongs immobility periods in both negative control (NC) and sh-5-HT1AR mice during the tail suspension test (TST) and forced swimming test (FST). In NC mice, 5-MeO-DMT and 5-OH-DMT significantly reduce immobility time in both TST (5-MeO-DMT: 80.21%; 5-OH-DMT: 83.06%) and FST (5-MeO-DMT: 31.03%; 5-OH-DMT: 54.46%). However, in sh-5-HT1AR mice, the effects are diminished, with 5-MeO-DMT showing 77.37% efficiency in TST and 37.07% in FST and 5-OH-DMT showing 68.76% efficiency in TST and 46.50% in FST (Fig. 6A and B and Table S3). In the sucrose preference test, both 5-MeO-DMT and 5-OH-DMT significantly counteract the reduction in sucrose preference induced by CUMS. However, in comparison to NC mice, only sh-5-HT1AR mice treated with 5-MeO-DMT show a decrease in sucrose preference (Fig. 6C and Table S3). The open-field test was conducted to assess anxiety-like behaviors. Results indicated that both 5-MeO-DMT and 5-OH-DMT increased the total distance traveled and time spent in the center, regardless of 5-HT1AR knockdown. However, 5-MeO-DMT reduced total distance after 5-HT1AR was knocked down (Fig. 6D and Table S3). Spatial learning and memory were assessed using the Morris water maze test. In NC and sh-5-HT1AR mice, 5-MeO-DMT and 5-OH-DMT decrease escape latencies (5-MeO-DMT: 124.47% efficiency; 5-OH-DMT: 146.30% efficiency) and increase target crossing times (5-MeO-DMT: 76.47% efficiency; 5-OH-DMT: 111.76% efficiency). sh-5-HT1AR mouse treatment with these 2 bufotenine derivatives increases escape latencies (efficiency of 5-MeO-DMT: 81.41%; efficiency of 5-OH-DMT: 81.93%), but only 5-OH-DMT reduces times across target (efficiency: 110.00%), compared to NC mice (Fig. 6E and Table S3). The findings indicate that both 5-MeO-DMT and 5-OH-DMT similarly alleviate CUMS-induced depressive-like and anxiety-like behaviors, as well as enhance learning and memory via 5-HT1AR. Furthermore, it is worth noting that in contrast to 5-MeO-DMT, 5-OH-DMT treatment resulted in somewhat reduced head-twitch response (HTR) and incremental horizontal locomotor activity (HLA) in mice (Fig. S10), indicating diminished hallucinogenic potential while preserving therapeutic antidepressant effects. 5-OH-DMT and 5-MeO-DMT exhibited similar improvement against depressive-like behaviors through 5-HT1AR. The (A) tail suspension test (TST), (B) forced swimming test (FST), (C) sucrose preference test (SPT), (D) open-field test (OFT), and (E) Morris water maze test (MWM) were performed in negative control (NC) and sh-5-HT1AR mice treated with or without chronic unpredictable mild stress (CUMS), 5-MeO-DMT, and 5-OH-DMT (n = 8). (F) TST, (G) FST, (H) SPT, and (I) OFT were performed in mice treated with or without 4-chloro-dl-phenylalanine (PCPA), 5-OH-DMT, and the 5-HT1AR antagonist WAY100635 (n = 12). All quantification data are presented as mean ± SEM. #P < 0.05 and ##P < 0.001 versus the control group; *P < 0.05, **P < 0.01, and ***P < 0.001 versus the model group. To further validate that 5-OH-DMT elicits antidepressant-like action via 5-HT-dependent mechanism, we generated a 4-chloro-dl-phenylalanine (PCPA)-induced mouse model of depression and anxiety and gave treatment with or without 5-OH-DMT (15 mg/kg) and 5-HT1AR antagonist WAY100635 before behavioral tests (Fig. S8B). As expected, compared with the control or model group, WAY100635 significantly increased immobility time in both TST and FST. In comparison, mice treated with 5-OH-DMT exhibited shorter immobility durations in these tests. However, the addition of WAY100635 to the PCPA and 5-OH-DMT group also prolonged the immobility time in both TST and FST (Fig. 6F and G). WAY100635 reduced sucrose preference compared to the control or model group. Conversely, treatment with 5-OH-DMT increased sucrose preference in mice, while this increase was reversed by WAY100635 (Fig. 6H). In addition, mice treated with WAY100635 showed less total distance traveled and less time spent in center compared to the control or PCPA mice in the open-field test. By contrast, 5-OH-DMT dramatically increased both the total distance and time spent in the center, whereas the administration of WAY100635 in the PCPA and 5-OH-DMT group significantly recovered these changes (Fig. 6I). These results reconfirmed that 5-OH-DMT ameliorates depressive-like behaviors through 5-HT1AR. Discussion The role of 5-HT1AR signaling in the therapeutic efficacy of antidepressants is well established [46–48]. Here, we provide the molecular structures of bufotenine derivatives in complex with 5-HT1AR, alongside a comprehensive analysis of their signaling behaviors at this receptor. This approach illuminates the precise relationship between the chemical configurations of bufotenine derivatives and their functional effects. Notably, bufotenine derivatives exhibit a more inclined orientation within the binding pocket compared to serotonin, with structural differences across binding sites influencing their interaction profiles. The structure–activity relationships reveal distinct contributions of key functional groups to 5-HT1AR binding and activation. The hydroxyl group at the 5-position of the indole ring serves as a critical hydrogen bond donor, potentially interacting with polar residues such as D1163.32 or S1995.42 within the OBP, thereby enhancing binding affinity and stabilizing the ligand–receptor complex [49–51]. This hydroxyl substitution distinguishes bufotenine derivatives from other tryptamines and may account for their unique pharmacological profile. Methoxy substitutions introduce additional steric bulk and electron-donating properties that can modulate receptor selectivity [52–54]. The methoxy group’s oxygen atom may participate in weak hydrogen bonding interactions with backbone amides or hydroxyl-containing residues, while its methyl component influences overall lipophilicity and membrane permeability [55]. Importantly, methoxy groups at different positions (e.g., 4-methoxy vs. 7-methoxy) create distinct binding orientations within the pocket, potentially explaining subtype selectivity between 5-HT1A and other serotonin receptors [37,56]. N,N-Dimethyl substitutions on the ethylamine side chain significantly impact both binding kinetics and efficacy. The methyl groups increase the basicity of the amine nitrogen, enhancing ionic interactions with the conserved D1163.32 that anchors most aminergic ligands. Additionally, the steric hindrance imposed by N-methylation may restrict conformational flexibility, favoring specific receptor conformations associated with particular signaling pathways. This could explain why certain N-methyl derivatives show biased signaling toward G-protein activation over β-arrestin recruitment, contributing to their therapeutic potential with reduced side effects [57]. These variations in structure modulate the activity and affinity of bufotenine derivatives at 5-HT1AR and 5-HT2AR. We speculate that 5-OH-DMT’s unique hydrogen bonding with I189ECL2 reduces β-arrestin recruitment, which may be associated with its low hallucination risk; however, this mechanistic explanation requires further validation through in-depth studies of receptor trafficking dynamics and electrophysiological consequences. Fluorescence recovery after photobleaching studies could quantify 5-HT2AR internalization rates and recycling kinetics following 5-OH-DMT treatment compared to classical hallucinogens. Additionally, whole-cell patch-clamp recordings in cortical pyramidal neurons would reveal the temporal profile of receptor activation and downstream effector coupling. Brain slice electrophysiology could assess network-level effects, particularly examining gamma oscillations in layer 2/3 cortical circuits that correlate with hallucinogenic experiences. Such studies would provide mechanistic validation of our molecular findings and establish the functional significance of reduced β-arrestin signaling. Furthermore, 2-photon calcium imaging in awake behaving animals could bridge molecular mechanisms with behavioral phenotypes, ultimately supporting the therapeutic potential of 5-OH-DMT derivatives. Importantly, bufotenine derivatives display unique conformations and distinct structural attributes relative to traditional antidepressants, enabling the development of structure-based bufotenine derivatives with selective 5-HT1AR activity and reduced affinity for 5-HT2ARs. Given that hallucinogenic effects are predominantly associated with 5-HT2AR activation, the comparatively moderate hallucinogenic potential of 5-HT1AR is notable. Since 5-MeO-DMT clearly targets 5-HT2AR, we focused on 5-OH-DMT in our in vivo experiments. Bufotenine derivatives demonstrate a significant enhancement in antidepressant efficacy in the CUMS model or PCPA model. Knockdown of hippocampal 5-HT1AR partly abolishes the effect of 5-OH-DMT in improving CUMS-induced depressive-like behaviors. However, the 5-HT1AR antagonist WAY100635 almost completely abolishes the antidepressant effect of 5-OH-DMT in the PCPA model. These differential effects might be explained by that except for the hippocampus, other brain regions also participate in 5-OH-DMT-exerted antidepressant effect. Moreover, PCPA-induced depression is clearly due to serotonin depletion, while the mechanism of CUMS-induced depression is more complex. Our findings confirm bufotenine derivatives as full agonists at 5-HT1AR. These insights underscore the potential of bufotenine derivatives as a promising avenue for targeted antidepressant development. Further study is needed to test 5-HT1A agonists such as buspirone or vilazodone in biological experiments to support any competitive advantage for bufotenine derivatives. Psychedelics are increasingly recognized as potential treatments for neuropsychiatric disorders. Classical psychedelics primarily target 5-HT2AR on cortical pyramidal neurons, influencing their hallucinogenic and subjective effects [58]. However, whether 5-HT2AR activation is indispensable for the neuroplastic and therapeutic potential of psychedelics remains debated. Growing evidence suggests that psychedelics exhibit complex polypharmacological profiles that extend beyond their 5-HT2AR-mediated hallucinatory actions. Receptors like TrkB, 5-HT2C, and 5-HT1A are increasingly acknowledged as crucial binding sites that enhance the plasticity and therapeutic effectiveness of psychedelics, separate from their hallucinogenic effects [59]. 5-HT1AR is implicated in the behavioral effects of tryptamine hallucinogens, especially 5-MeO-DMT, aligning with some findings from our study [37]. Psychedelics are thus likely to act through multiple pathways, with the specific receptor profiles engaged by each compound potentially optimizing their therapeutic utility across various disorders. Our findings demonstrate that bufotenine derivatives exert antidepressant effects primarily through 5-HT1AR. A diverse array of chemically distinct compounds is essential for developing new drugs targeting 5-HT1AR, with tailored efficacy, activity, and selectivity profiles. Each psychedelic compound can elicit unique introspective effects, shaped by genetic differences that influence drug metabolism and individual responses. Although psychedelics often act on multiple molecular targets, their specific effects vary with chemical structure. Thus, identifying the optimal psychedelic-inspired treatment for a given condition is not always straightforward. Expanding the chemical landscape by considering both the subjective effects and structural diversity of these compounds is crucial for advancing personalized therapeutics. Conclusion In conclusion, our integrated structural and functional analyses reveal how bufotenine derivatives—5-MeO-DMT, 5-OH-DMT, and 5-OH-TMT—selectively engage and activate 5-HT1AR at high resolution. These compounds demonstrate robust antidepressant efficacy in vivo while exhibiting attenuated hallucinogenic properties, largely attributed to their specific modulation of 5-HT1A-mediated G-protein signaling. Collectively, our findings establish a mechanistic framework for the rational design of 5-HT1A-targeted therapeutics and support the potential of bufotenine derivatives as promising candidates for the development of safer and more effective antidepressant and anxiolytic drugs. Methods Creating compounds through chemical reactions Compound 1 (5-MeO-DMT) was synthesized by reacting (4-methoxyphenyl)hydrazine hydrochloride (5.0 mmol) with 4,4-diethoxy-N,N-dimethyl-1-butylamine (5.25 mmol) in water and sulfuric acid under N2 at 37 °C for 14 h. The mixture was basified (pH 10) and extracted with ethyl acetate. The crude product was purified via silica gel chromatography (dichloromethane [DCM]:methanol [MeOH] = 30:1) to yield a brown-yellow paste (684.4 mg, 62.7%). 1H nuclear magnetic resonance (NMR) (500 MHz, CDCl3) δ 7.94 (s, 1H), 7.24 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 2.4 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.85 (dd, J = 8.8, 2.4 Hz, 1H), 3.86 (s, 3H), 2.93 to 2.88 (m, 2H), 2.65 to 2.61 (m, 2H), 2.34 (s, 6H). 13C NMR (500 MHz, CDCl3) δ 154.07, 131,56, 127.74, 122.58, 112.00, 100.67, 59.79, 56.00, 44.97, 23.21. Compound 2 (5-OH-DMT) was prepared using 5-benzyloxyindole (10 mmol) and oxalyl chloride (20 mmol) in anhydrous diethyl ether at room temperature for 30 min. The red solid was collected by filtration, washed with ether, and dried under vacuum to afford 5-benzyloxy-3-indol-glyoxylylchloride. An aqueous NaOH solution was added dropwise to a suspension of 5-benzyloxy-3-indol-glyoxylylchloride (10 mmol) and dimethylamine hydrochloride (42.9 mmol) in ether at 25 °C for over 30 min. The crude product was obtained by filtration. The product was hydrogenated (10% Pd/C, H2, 24 h), filtered, and purified via silica gel (DCM:MeOH = 30:1) to give 6.1 g of the product (92% yield). The product (35 mg, 0.15 mmol) was reduced with LiAlH4 (9 mmol) in tetrahydrofuran at 0 °C, refluxed for 4 h, and then stirred at 40 °C for 10 h. After NaOH quenching and workup, column chromatography (CH2Cl2:MeOH = 10:1) gave compound 2 (5-OH-DMT) as a yellow-brown oil (85% yield). 1H NMR (dimethyl sulfoxide-d6 [DMSO-d6], 500 MHz) and 13C NMR confirmed the structure [60]. Compound 3 (5-OH-TMT) was obtained by methylating compound 2 (20 mmol) with methyl iodide (120 mmol) in MeOH under nitrogen for 24 h, followed by silver chloride treatment to remove iodide. After extraction and chromatography (DCM:MeOH = 20:1), 3.4 g of the product was isolated (47.9% yield). 1H NMR (DMSO-d6, 500 MHz) and 13C NMR supported successful quaternization [60]. Construction To achieve insert cell expression, Synbio Technologies optimized the human wild-type 5-HT1A gene codons. A thermally stable apocytochrome b562 RIL was inserted at the N-terminal of human 5-HT1AR to boost receptor expression [61]. The proteins included affinity markers like the N-terminal Flag and His tags. It was shown that L125W alterations in 5-HT1A improved thermal stability [62]. The Vazyme Biotech ClonExpress II One-Step Cloning Kit cloned 5-HT1AR into pFastBac. The receptor’s N terminus was 24 residues short. Dominant-negative human Gαi1 was produced with mutations S47N, G203A, A326S, and E245A using site-directed mutagenesis. Mutations increase the dominant-negative impact by destroying the βγ subunits’ stabilizing salt bridge [40]. Cloned pFastBac vectors include human dominant-negative Gαi1 (DNGαi1), Gβ1, and Gγ2 genes. A modified pFastBac vector cloned scFv16. The vector’s N-terminus includes the GP67 secretion signal peptide. While being built, insect cell expression vectors created these structures. Cell culture and protein expression At 27 °C, High Five insect cells (Hi5, Invitrogen) were grown in ESF 921 serum-free medium (Expression Systems). Agilent HEK 293T cells were cultured in Thermo Fisher’s Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). A room with regulated humidity, 5% CO2, and 37 °C temperature housed the cultivation. The Bac-to-Bac Baculovirus Expression System from Thermo Fisher developed baculoviruses. Human genes 5-HT1A, DNGαi1, Gβ1, Gγ2, and scFv16 were coexpressed in High Five cells using Expression Systems’ baculovirus technique. Cell cultures were grown to 2 to 3 million cells/ml and evenly treated to 5 baculoviruses. After 48 h of infection, centrifuged cells were kept at −80 °C for examination. Purification of protein complexes Cryopreserved cells were lysed in buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 10% glycerol, 10 mM MgCl2, and 5 mM CaCl2) with EDTA-free protease inhibitors. After Dounce homogenization, 5-HT1A–Gi–scFv16 complexes were formed by adding 25 mU/ml apyrase and 100 μM ligand at room temperature for 1.5 h. Membranes were solubilized in 0.5% lauryl maltose neopentyl glycol and 0.1% cholesteryl hemisuccinate at 4 °C for 2 h and clarified by ultracentrifugation (30,000 rpm, 30 min). The supernatant was incubated with Talon beads for 2 h at 4 °C. After washing with low imidazole buffer, bound complexes were eluted with 250 mM imidazole. The eluate was concentrated using a 100-kDa cutoff filter and purified by size-exclusion chromatography (Superose 200 Increase 10/300 GL). Eluted fractions were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Figs. S1 to S3). For cryo-EM investigation, receptor–Gi-protein complex samples were combined and condensed. Cryo-EM data acquisition Purified 5-MeO-DMT-, 5-OH-DMT-, and 5-OH-TMT-bound 5-HT1A–Gi–scFv16 complexes (12, 10, and 13 mg/ml) were vitrified on glow-discharged Quantifoil grids using a Vitrobot at 4 °C. Cryo-EM data were acquired on a Titan Krios G4 (300 kV) with a Falcon 4i detector and Selectris X, collecting 13,026, 5,233, and 5,387 electron event representation (EER) movies at 0.73 Å/pixel, 10 e−/Å2/s, with defocus from −0.8 to −1.8 μm. Image processing and 3-dimensional reconstruction Motion correction was performed using MotionCor2 [63,64], and contrast transfer function estimation was done with CTFFIND [65] in cryoSPARC. Low-quality micrographs (>4.0 Å or carbon contaminated) were excluded. Particle picking (blob, Topaz, template) and 2-dimensional classification identified high-quality particles for ab initio reconstruction and heterogeneous refinement. After merging and de-duplication, 180,694, 195,003, and 139,905 particles were refined for the 5-MeO-DMT, 5-OH-DMT, and 5-OH-TMT complexes, respectively, yielding global resolutions of 2.63, 2.54, and 2.59 Å, respectively. Local refinement on the receptor achieved 2.75, 2.55, and 2.74 Å, respectively, followed by DeepEMhancer [66] post-processing (Figs. S1 to S3). Model building and refinement The density maps were fitted with structural models of 5-HT1A, Gαi, Gβ, Gγ, and scFv16 from PDB entries 7E2Z and 7YS6 (Fig. S4) [41]. Initial fitting into locally refined receptor maps was performed in UCSF Chimera [67], followed by iterative manual adjustments in COOT [68] and automated refinement in PHENIX [69]. G protein and receptor models were further fitted into B-factor-sharpened maps, refined in COOT and PHENIX, and subjected to additional reconstruction using ISOLDE [70] and PHENIX with torsion restraints. Final models were validated via PHENIX cryo-EM validation (Table S1). Figures were prepared using Chimera, ChimeraX [71], and PyMOL (Schrödinger, LLC.). Molecular docking The molecular docking models were constructed using the 5-HT2A structures (PDB: 7RAN). The models were generated by removing all ligands and water molecules from these structures. The PubChem database (https://pubchem.ncbi.nlm.nih.gov/) was used to download the structures of the small-molecule ligands of interest. At a physiological pH of 7.4 and using AMBER ff 14SB parameters [72], protonation states were assigned using H++ 3.2v (http://newbiophysics.cs.vt.edu/H++/). Then, the Chiron tool was used to decrease energy in the protein structure [73]. At the center of X: 130.464, Y: 116.935, and Z: 87.163, the grid box covers virtually all of the pocket residues; the 5-HT1A ligand docking grid line was X: 16.833, Y: 12.877, and Z: 14.753 (Å). Using AutoDock Vina (version 1.1.2) [74], docking computations were carried out. The ChimeraX software was used to view the docked protein–ligand structures. Animals Adult C57BL/6 male mice (6 to 8 weeks) were purchased from QingLongShan (Nanjing, China). The mice were individually housed at 18 to 22 °C with water and food ad libitum and at a 12:12 h light cycle. Ethics statement All experiments involving animals were conducted according to ethical policies and procedures approved by the Animal Care and Use Committee of Nanjing University of Chinese Medicine (Nanjing, China) (Approval No. A220404). Stereotactic injections Adeno-associated viruses (AAVs) encoding AAV-Syn-eGFP-scramble shRNA (1.26 × 1013 viral genomes/ml) and AAV-Syn-eGFP-sh-5-HT1AR (1.10 × 1013 viral genomes/ml) were generated by OBIO Technology (Shanghai, China). Mice received stereotactic injections into the hippocampal region at the following coordinates relative to the bregma: anterior/posterior, −2 mm; mediolateral, ±1.5 mm; and dorsoventral, −1.8 mm [75]. Animals were injected with either 500 nl of viruses into both hemispheres to breed hippocampus-specific 5-HT1AR knockdown (sh-5-HT1AR) mice and NC mice. After 3 weeks, the efficiency of postinfection was verified by enhanced green fluorescent protein (eGFP) fluorescence and relative 5-HT1AR messenger RNA level. For messenger RNA detection, hippocampal RNA was isolated and first-strand complementary DNA was synthesized using HiScript II Q RT SuperMix. Quantitative real-time polymerase chain reaction (PCR) was performed with ChamQ SYBR qPCR Master Mix in CFX Connect Real-Time PCR Detection System (Bio-Rad, Redmond, USA). The primers used in this study were as follows: 5-HT1AR F, CATCGCGCTAGACAGGTACTG; 5-HT1AR R, CAATGAGCCAAGTGAGCGAGA; β-actin F, GTGACGTTGACATCCGTAAAGA; and β-actin R, GCCGGACTCATCGTACTCC. CUMS model and treatment Mice were divided into the control or CUMS model group. For the CUMS model group, mice were exposed to randomized stressors at least once a day over 5 weeks, including 24-h water/food deprivation, reversed light/dark cycle, 24-h soiled/empty cage, 24-h cage tilt, 5-h confinement, 5-min cold swimming, and 6-h noise (80 dB). The control group was housed under normal conditions and switched to individual housing only during the reversed light/dark cycle and noise phase. At week 6, CUMS model mice were randomized into subgroups to receive saline solution (vehicle), 15 mg/kg 5-MeO-DMT, and 15 mg/kg 5-OH-DMT for the next 1 week, respectively. The doses chosen were based on previous preclinical experiments by us and others [76,77]. Drugs were dissolved in saline solution containing 0.1% DMSO and disrupted by ultrasound and then immediately administered via intraperitoneal injection. Then, mice with 1-week administration were tested for all behaviors. PCPA model and treatment Mice were randomly divided into the following 6 groups: control, WAY100635, PCPA, PCPA + WAY100635, PCPA + 5-OH-DMT, and PCPA + 5-OH-DMT + WAY100635. Mice in the control group were fed with saline solution containing 0.1% DMSO (vehicle) for 3 d. Mice that were injected subcutaneously with 150 mg/kg PCPA twice daily for 3 d developed symptoms of depression. For pharmacological treatment, mice were treated with 15 mg/kg 5-OH-DMT via intraperitoneal injection for 3 d during PCPA procedures. For WAY100635 treatment, mice were injected intraperitoneally with 1 mg/kg WAY100635 for 3 d. PCPA, 5-OH-DMT, and WAY100635 were dissolved in saline solution containing 0.1% DMSO and disrupted by ultrasound. Then, mice were tested for all behaviors. Behavior tests Tail suspension test Mice were suspended by placing adhesive tape 1 cm from the tail tip. The immobility time was recorded for the last 4 min of the total 6 min. Forced swimming test Mice were placed in a cylinder filled with water (23 ± 1 °C) for 6 min. The immobility time was recorded during the last 4 min of the test. Sucrose preference test Mice were habituated with 1% sucrose and water from 2 different bottles for 3 d. These 2 bottles were placed on randomly assigned sides of the cage every day to eliminate side preference. Then, each mouse had free access to 1% sucrose and water from 2 bottles for 3 h. The total volume of liquid consumed from each bottle was measured. Sucrose preference was calculated by the following formula: sucrose preference (%) = sucrose consumption/(sucrose + water consumption) × 100%. Morris water maze test The water maze was divided into 4 quadrants, and mice were trained to escape from water by swimming to the platform for 4 trials per day with different start points for 4 consecutive days. On day 5, the test was conducted and mice searched freely for 1 min starting from the opposite quadrant of the platform. The latencies to reach the platform and times cross target was recorded using the software Morris. Open-field test Mice were placed in the center of an open-field box. A total of 5-min video was recorded to observe the locomotor activity of mice. The total distance traveled in the field and the time spent in the center zone by mice were measured. Side effect detection Mice were given 25 mg/kg 5-MeO-DMT or 25 mg/kg 5-OH-DMT by intraperitoneal injection. Then, HTR and HLA were immediately tested. Mice were placed into the observation arena (25 × 25 × 40 cm) under low-light conditions. The number of head-twitch events and total distance were respectively recorded for 10 and 30 min. For the HTR test, the number of head twitches was examined by 2 observers blinded to the treatments via video recordings. For the HLA test, the total distance traveled was measured by using tracking software to process video recordings. GloSensor cAMP assay The downstream Gαi signaling of 5-HT1A was assessed using the GloSensor cAMP assay (Promega). HEK 293T cells were cultured in DMEM with 10% FBS and 1% penicillin–streptomycin at 37 °C and 5% CO2. Cells were transfected with 5-HT1A constructs and the GloSensor-22F biosensor at a 3:2 ratio. After 24 h, cells were resuspended in CO2-independent medium with 2% GloSensor reagent and plated at 3.5 × 105 cells/ml (20 μl/well) into 384-well plates. After 1-h incubation, forskolin (1 μM) and test ligands were added, and luminescence was immediately recorded using an EnVision plate reader (PerkinElmer). Inositol phosphate accumulation assay The downstream Gαq signaling of 5-HT2A was evaluated using the IP-One HTRF assay (Cisbio). HEK 293T cells were cultured in DMEM with 10% FBS and 1% penicillin–streptomycin at 37 °C, 5% CO2. After 24 h of transfection, cells were resuspended in stimulation buffer (8 × 105 cells/ml) and plated at 7 μl/well into 384-well plates. Ligands diluted in buffer (7 μl) were added and incubated for 1 h at 37 °C. IP-One-d2 and anti-IP-One cryptate (3 μl each) were then added, followed by 30-min incubation at room temperature. HTRF signals were measured using an EnVision reader (PerkinElmer). Statistical analysis For all behavioral studies, mice were randomly assigned to the groups. In addition, investigators were blinded to the group until data had been collected. GraphPad Prism 9 was used to analyze all of the functional research data, and the results are provided as mean ± standard error of the mean from at least 3 separate trials. An evaluation of the concentration–response curves was carried out using a logistic equation with 3 parameters. Calculations of pEC50 values were performed with the use of the sigmoid 3-parameter equation. In order to assess the significance, a 1-way or 2-way analysis of variance was conducted, followed by Bonferroni’s or Dunnett’s post hoc test. Differences were considered significant when P < 0.05 and are shown as *P < 0.05, **P < 0.01, or ***P < 0.001. Ethical Approval All institutional and national guidelines regarding the care and use of animals were adhered to.